Turkish Version of Digital Eye Strain Questionnaire (DESQ)
Sponsor
Alanya Alaaddin Keykubat University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06054542
Collaborator
(none)
130
8
Study Details
Study Description
Brief Summary
The aims of this study were to perform cultural adaptation of the DESQ and provide information regarding the factor structure, reliability and validity of the instrument in Turkish speaking adults.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Study Design
Study Type:
Observational
Anticipated Enrollment
:
130 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Validity and Reliability of the Turkish Version of Digital Eye Strain Questionnaire (DESQ)
Anticipated Study Start Date
:
Oct 1, 2023
Anticipated Primary Completion Date
:
May 1, 2024
Anticipated Study Completion Date
:
Jun 1, 2024
Outcome Measures
Primary Outcome Measures
- DESQ [10 minutes]
Digital Eye Strain Questionnaire (DESQ) is a thirteen-item self-report scale in a yes-no format designed to offer a measure of complaints related to digital eye strain syndrome (DES)
Eligibility Criteria
Criteria
Ages Eligible for Study:
18 Years
to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
-
Between the ages of 18-65 years
-
People who spend two or more continuous hours a day on their digital devices (computer, tablet, smartphone) or use more than one device
Exclusion Criteria:
-
History of ophthalmic surgery or active ocular disease
-
Participants who did not understand the instructions or did not sign a consent form were excluded
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Alanya Alaaddin Keykubat University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
Ayse Unal,
Assoc. Prof.,
Alanya Alaaddin Keykubat University
ClinicalTrials.gov Identifier:
NCT06054542
Other Study ID Numbers:
- 20.09.2023/DESQ
First Posted:
Sep 26, 2023
Last Update Posted:
Sep 26, 2023
Last Verified:
Sep 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms: